Paul Hopper is an accomplished executive and entrepreneur with extensive experience in the life sciences sector. As the Executive Chairman and Founder of Radiopharm Theranostics, Chimeric Therapeutics, and Imugene Limited, Paul Hopper has spearheaded innovative developments in CAR-T cell therapies and other therapeutic approaches. Additionally, Paul Hopper has held leadership roles at Life Science Portfolio Managers and Arovella Therapeutics, and previously contributed to investment banking as Head of the Australia Desk and Life Science Practice at Cappello Group. Paul Hopper's academic background includes advanced management studies at Harvard Business School and a Bachelor of Arts in Political Science and Government from UNSW.